Release time：May 26, 2021
On May 26, 2021, Dr. Datao Liu, founder and CEO of Mabwell, was invited to attend DIA 2021 Annual Meeting and Exhibition. On May 20, Dr. Datao Liu delivered a speech entitled "Significance of Risk Control and Related Technical Essentials of Pharmaceutical Compounding for the Industry" at the Symposium on Risk Control Technology of Pharmaceutical Compounding co-organized by the China Association for Drug Administration and Cytiva, and attended the publishing ceremony of Risk Control-Related Technical Essentials of Pharmaceutical Compounding (referred to as the Compounding Guidelines) as the editor. On May 22, Mabwell, as a co-organizer, participated in a special event of phase I clinical study co-organized by Fudan University Shanghai Cancer Center & Clinical Service Center Co., Ltd., and Dr. Datao Liu discussed with several experts during the special session of "Talk on the Innovative Model of New Drug R&D".
Symposium on Risk Control Technology of Pharmaceutical Compounding
Based on the current advanced pharmaceutical compounding technology, the symposium had an in-depth discussion on the critical process quality control points and risk management and control, and shared technology and experience on these aspects of pharmaceutical compounding. At the symposium, the Compounding Guidelines was successfully published, and Mr. Xue Bin, Director of International Exchange Center of National Medical Products Administration, delivered a speech at the opening ceremony of the symposium.
Mr. Wei Zhang, President of the China Association for Drug Administration and Research and Editor-in-Chief of the Compounding Guidelines, as well as several editors and senior experts from the pharmaceutical industry, were invited to give speeches at the symposium. Dr. Datao Liu, as the editor of the Compounding Guidelines, delivered a speech entitled "Significance of Risk Control and Related Technical Essentials of Pharmaceutical Compounding for Industry", and analyzed and discussed the compounding technology and risk control from the perspective of enterprise managers.
Dr. Datao Liu delivered a speech
Launch of Compounding Guidelines
Special Event of Phase I Clinical Study Co-organized by Fudan University Shanghai Cancer Center & Clinical Service Center Co., Ltd.
On May 22, Mabwell participated in a special event of phase I clinical study co-organized by Fudan University Shanghai Cancer Center & Clinical Service Center Co., Ltd. In the special session of "Talk on the Innovative Model of New Drug R&D", Dr. Datao Liu and several experts in the industry expressed their views, jointly discussed the strategic considerations such as submitting application in both China and the US or in multiple nations by combining with the R&D pipelines of their respective enterprises, elaborated the needs of declaration in China and US and international multi-center clinical trials, and put forward the difficulties and challenges.
As an innovative biopharmaceutical company with a whole industry chain, Mabwell attaches importance to every step from R&D to marketing. The company now has more than 10 investigational biologics in different R&D stages, and the treatment fields include auto-immune diseases, tumors, metabolic disorders, ophthalmologic diseases and infectious diseases. Of these, 4 biologics have entered into the stage of critical clinical trials. In the future, we will further strengthen the innovation capacity in all links of R&D, and bring high-quality innovative biologics to more patients.
About DIA 2021
The 2021 DIA China Annual Meeting is based on the twin trends of internationalization and domestic innovation of new drug R&D, with the theme of "Embrace Globalization and start from Innovations". The content comprehensively focuses on regulatory policy innovation, science and technology innovation, and talent innovation. Hand in hand with the world's top experts and colleagues in the field of pharmaceutical R&D gathered at Jinji Lake. China's drug R&D has been gradually integrated into globalization for the past 12 years, let's start again from innovations!
